Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice-Reference-Cited by-同舟云学术

Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice

Published:2015-08-21 Issue:2 Volume:63 Page:512-523
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Miethke Alexander G.¹²,Zhang Wujuan³,Simmons Julia¹,Taylor Amy E.¹,Shi Tiffany¹,Shanmukhappa Shiva Kumar³²,Karns Rebekah⁴,White Shana⁴,Jegga Anil G.⁴²,Lages Celine S.¹,Nkinin Stephenson³,Keller Bradley T.⁵,Setchell Kenneth D.R.³²

Affiliation:

1. Division of Pediatric Gastroenterology; Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center; Cincinnati OH

2. Department of Pediatrics; University of Cincinnati College of Medicine; Cincinnati OH

3. Division of Pathology and Laboratory Medicine; Cincinnati Children's Hospital Medical Center; Cincinnati OH

4. Division of Biomedical Informatics; Cincinnati Children's Hospital Medical Center; Cincinnati OH

5. Consultant to Shire plc; San Diego CA

Funder

National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK)

foundation “PSC Partners seeking a cure” supported this study (to A.G.M.). Lumena Pharmaceutical Inc. (now Shire plc) provided research funds to A.G.M and K.D.R.S

National Institutes of Health

PHS

Research Flow Cytometry Core in the Division of Rheumatology at Cincinnati Children's Hospital Medical Center

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.27973/fullpdf

Reference38 articles.

1. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond;Beuers;J Hepatol,2015

2. Pathogenesis of cholestatic liver disease and therapeutic approaches;Hirschfield;Gastroenterology,2010